Questions readers actually arrive with

What is CJC-1295 and how was it developed?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), built from the first 29 amino acids of the human hormone with four amino-acid substitutions and a chemical handle on its C-terminus that lets it covalently couple to serum albumin in the bloodstream. It was developed by ConjuChem in the early 2000s as the lead candidate from a screen of GHRH-albumin bioconjugates, with the 2005 Jetté paper describing the lead-optimization work and the 2006 Teichman paper publishing the first-in-human PK/PD data ^[1][2]. ConjuChem's intended development indication was HIV-associated visceral adiposity, the same condition for which tesamorelin (a related GHRH analog) was later approved by the FDA ^[11].

How does CJC-1295 actually work at the molecular level — what does the DAC modification do?

CJC-1295 binds the GHRH receptor on anterior pituitary somatotrophs and triggers them to release growth hormone via a Gs/cAMP/PKA signaling cascade ^[1][3]. Downstream, the released GH stimulates the liver to produce IGF-1, which mediates most of GH's anabolic effects ^[8]. The DAC (Drug Affinity Complex) modification is a chemical handle — a maleimide group attached to a C-terminal lysine — that, after subcutaneous injection, reacts spontaneously with the single free thiol on serum albumin (at cysteine 34) to form a covalent peptide-albumin conjugate. The conjugate then circulates with albumin for days instead of being cleared in minutes. The four backbone substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) protect the peptide from enzymatic cleavage and preserve the α-helical conformation the receptor recognizes ^[1].

What is the difference between CJC-1295 with DAC and without DAC?

The two share the same 30-amino-acid backbone with the four protective substitutions. The DAC variant has the maleimide-albumin handle on its C-terminus; the non-DAC variant does not. Pharmacologically the difference is enormous: the DAC variant has a plasma half-life of 5.8 to 8.1 days in healthy adults ^[2], while the non-DAC variant has a half-life of about 30 minutes ^[1]. Native human GHRH, for comparison, has a half-life of about 7 minutes. Research-chemical channels sometimes label the non-DAC variant 'CJC-1295 without DAC' as if it were a dosage form, but the two are not interchangeable. The DAC variant is what the Teichman 2006 Phase 1 paper studied; almost all the published human evidence on 'CJC-1295' is on the DAC variant ^[2][3][8].

How long does CJC-1295 stay in the body?

For the DAC variant, the estimated mean plasma half-life is 5.8 to 8.1 days in healthy adults ^[2]. The upper bound of that range approaches the half-life of serum albumin itself (about 19 to 21 days), since the covalent peptide-albumin conjugate is essentially being cleared at the rate of the carrier protein. Pharmacodynamic GH and IGF-1 effects routinely outlast measurable plasma peptide concentrations — in the Teichman cohort, mean GH was elevated for at least six days after a single dose and IGF-1 for nine to eleven days ^[2]. The non-DAC variant clears in well under an hour.

What does the published human research literature actually show?

The published human evidence consists essentially of three papers from one Phase 1 program (Teichman 2006 on dose-response PK, Ionescu 2006 on preserved pulsatility, Sackmann-Sala 2009 on serum proteome shifts), one terminated Phase 2 trial without published efficacy data (NCT00267527), and the foundational native-GHRH and GHRH-stimulation-test literature that contextualizes the mechanism ^{[2][3][8][9][12]}. The Phase 1 data are clean and consistent: single subcutaneous doses raise GH for at least six days and IGF-1 for nine to eleven days, pulsatile GH architecture is preserved, and short-term adverse events are mild and local ^[2]. The Phase 2 trial in HIV-associated visceral adiposity was terminated in October 2006 and primary efficacy endpoints were never published ^[9]. No Phase 3 trial exists.

Why was the CJC-1295 Phase 2 trial halted, and was it ever restarted?

NCT00267527, a randomized double-blind placebo-controlled trial sponsored by ConjuChem in 192 adults with HIV-associated visceral adiposity, was terminated in October 2006 after a participant died of an acute coronary event approximately two hours after the eleventh weekly dose ^[9]. Independent review attributed the death to pre-existing undiagnosed coronary artery disease and judged it not study-drug related. The program was not restarted. ConjuChem did not pursue further sponsor-led clinical development of CJC-1295, and twenty years later no successor sponsor has taken it through Phase 2 or Phase 3. This trial remains the largest CJC-1295 human exposure on the public record; its primary efficacy endpoints have never been published.

How is CJC-1295 detected in anti-doping testing?

Validated detection methods now exist for both equine plasma and human urine. The equine methods are the most developed: Timms and colleagues 2019 published an immuno-polymerase chain reaction (I-PCR) assay using monoclonal antibodies against CJC-1295 with a screening limit of 0.8 pg/mL and a confirmatory LC-MS/MS method at 180 pg/mL in 1 mL of plasma ^[5][6]. The analytical challenge these methods solve is that CJC-1295 covalently bound to albumin cannot be detected by conventional intact-peptide mass spectrometry; immunoaffinity capture concentrates the bound conjugate before tryptic digestion releases diagnostic peptide fragments. Comparable nano-LC-HRMS/MS methods have been developed for human urine ^[17]. The argument that CJC-1295 'cannot be detected' is no longer accurate.

Is CJC-1295 FDA approved for any medical use?

No. CJC-1295 has never been approved by the FDA for any indication. The only Phase 2 trial was terminated in 2006 without published efficacy data, and no Phase 3 trial has been conducted ^[9]. There is no FDA-labeled dose, no USP or NF monograph, and no approved manufacturer. The structurally related GHRH analog tesamorelin is the only FDA-approved member of the GHRH-analog class, approved for HIV-associated lipodystrophy at a 2 mg daily subcutaneous dose ^[11]; tesamorelin is mentioned in the CJC-1295 literature as the class comparator that established what visceral-fat efficacy CJC-1295's terminated Phase 2 program had been pursuing.

What did the 2024 FDA Pharmacy Compounding Advisory Committee say about CJC-1295?

FDA's Pharmacy Compounding Advisory Committee reviewed CJC-1295 at its October 29, 2024 meeting and a December 4, 2024 follow-up meeting ^[14][20]. The October briefing cited immunogenicity risk from peptide aggregates and impurities — with the injectable subcutaneous route considered a particularly high-risk presentation — and nonclinical toxicology findings including reduced hemoglobin, elevated cholesterol, injection-site inflammation and necrosis, and pituitary DNA-damage signals. Clinical adverse-event signals cited included increased heart rate and systemic vasodilatory reactions. The committee did not recommend inclusion of CJC-1295 on the 503A bulk drug substances list. The December follow-up consolidated public comment and reiterated insufficient evidence to support routine 503A compounding access, citing the roughly twenty-year absence of sponsor-led clinical development since the 2006 Phase 2 termination ^[20].

What happened to CJC-1295's 503A compounding status in 2026?

In April 2026, FDA removed CJC-1295 from Category 2 of the 503A bulk drug substances list following withdrawal of its nomination ^[15]. CJC-1295 was not moved to Category 1 (substances permitted for compounding). The substance is now in a regulatory gray zone — neither explicitly authorized for compounding nor on an active prohibition list — with no FDA-approved indication and no USP/NF monograph. The practical effect is that traditional 503A compounding pharmacies cannot rely on it being a permitted bulk substance. This change followed several years of FDA scrutiny of the GH-secretagogue peptide class, including the 2024 PCAC reviews and the July 2025 Class II recall of a compounded CJC-1295 injectable for lack of assurance of sterility ^[14][16].

Why does the FDA cite immunogenicity as a concern for compounded CJC-1295?

Peptide therapeutics can provoke anti-drug antibody responses, particularly when aggregates or impurities are present in the injected product. The FDA's 2024 PCAC briefing on CJC-1295 articulated this specifically: peptide aggregation during storage and reconstitution, and impurities from non-pharmaceutical-grade fill-finish processes, can drive immunogenicity, with the injectable subcutaneous route considered the highest-risk presentation ^[14]. The July 2025 Class II FDA recall on a specific brand of compounded CJC-1295 injectable for lack of assurance of sterility provided a concrete real-world quality-failure data point illustrating those concerns ^[16]. The underlying analytical reality is that CJC-1295 covalently couples to albumin in vivo, so any anti-drug antibody response could in principle target peptide-albumin conjugates rather than free peptide — a complication that does not arise for most non-DAC peptide therapeutics.

Why is CJC-1295 often paired with ipamorelin in the research literature?

The mechanistic rationale traces back to Bowers and colleagues 1990, who showed that combining a GHRH agonist with a GHRP (ghrelin-receptor agonist) produces a GH response several-fold larger than either alone in healthy adults ^[10]. The two receptor classes — GHRHR (Gs/cAMP) and GHS-R1a (Gq/IP3/Ca²⁺) — signal through independent second-messenger systems whose downstream effects on somatotroph vesicular release are additive. Ipamorelin is the most-studied GHRP pairing because it is relatively selective for GHS-R1a and produces minimal cortisol or prolactin elevation compared to earlier GHRPs like GHRP-6 or hexarelin. The CJC-1295 + ipamorelin pairing therefore inherits the Bowers 1990 synergy mechanism while keeping the off-target endocrine profile minimal ^[10]. Note that no Phase 2 or Phase 3 trial of the CJC-1295 + ipamorelin combination has been conducted; the synergy claim rests on the foundational dual-receptor pharmacology, not on a combination trial.

How does CJC-1295 compare to tesamorelin, the FDA-approved GHRH analog?

Both are GHRH-receptor agonists built on modifications of the GRF(1-29) backbone. The structural difference is that tesamorelin uses an N-terminal trans-3-hexenoyl group for protease protection rather than the four-position substitution-plus-DAC-handle strategy used in CJC-1295. The clinical difference is larger: tesamorelin is FDA-approved at 2 mg subcutaneously daily for HIV-associated lipodystrophy, with a published randomized clinical trial showing 15 to 20 percent reduction in visceral adipose tissue over 26 weeks ^[11]. CJC-1295 has no approved indication, no Phase 2 efficacy data in the peer-reviewed literature, and a half-life of 5.8 to 8.1 days versus tesamorelin's daily-dosing PK profile ^[2][11]. They occupy the same pharmacological class but very different regulatory positions.

What is CJC-1295's WADA status for tested athletes?

CJC-1295 is listed under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) of the WADA Prohibited List and has been since detection methods first appeared in the analytical literature ^[17]. The S2 classification means CJC-1295 is prohibited at all times — both in-competition and out-of-competition — for any athlete subject to the WADA Code. Validated detection methods exist for both human urine (nano-LC-HRMS/MS) and equine plasma (I-PCR plus immunoaffinity LC-MS/MS), so the analytical argument that exogenous CJC-1295 cannot be distinguished from endogenous GHRH no longer holds ^[5][6][17].

Does CJC-1295 affect sleep?

Foundational neuroendocrine work from the early 1990s established that pharmacological activation of the GHRH receptor in healthy male subjects increased duration and intensity of NREM stage 3-4 (slow-wave) sleep ^[18]. This is the principal mechanistic rationale for the recurring claim that GHRH analogs might modulate sleep architecture. However, no controlled human sleep-architecture study of CJC-1295 itself has been published. The inference from native-GHRH data to CJC-1295 is plausible on receptor pharmacology grounds but is not directly supported by a trial in the published record.